Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year
P. M. A. Calverley, R. Pauwels, J. Vestbo, P. Jones, N. B. Pride, A. Gulsvik, J. Anderson, C. Maden, on Behalf of the TRISTAN Study Group (Liverpool, London, Uxbridge, United Kingdom; Gent, Belgium; Hvidovre, Denmark; Bergen, Norway)
Source: Annual Congress 2002 - COPD - Drug therapy 1
Session: COPD - Drug therapy 1
Session type: Thematic Poster Session
Number: 1572
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. M. A. Calverley, R. Pauwels, J. Vestbo, P. Jones, N. B. Pride, A. Gulsvik, J. Anderson, C. Maden, on Behalf of the TRISTAN Study Group (Liverpool, London, Uxbridge, United Kingdom; Gent, Belgium; Hvidovre, Denmark; Bergen, Norway). Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year. Eur Respir J 2002; 20: Suppl. 38, 1572
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain Source: Eur Respir J 2006; 28: Suppl. 50, 683s Year: 2006
Comparative study of two years treatment with salmeterol alone and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004
Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003
Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
A comparison of salmeterol xinafoate (SX) plus fluticasone propionate (FP) and slow-release theophylline (Theo) plus FP in the treatment of stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 31s Year: 2006
A comparison of salmeterol xinafoate (SX) plus beclomethasone dipropionate (BDP) and theophylline (Theo) plus BDP in the treatment of moderate chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice Source: Eur Respir J 2002; 20: 819-825 Year: 2002
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009
The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 602s Year: 2004
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Comparative study of one-year treatment with salmeterol along, and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructi e pulmonary diseases (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 286s Year: 2003
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations Source: Eur Respir J 2003; 21: 68-73 Year: 2003